Connect
MJA
MJA

Ensuring safety of the 2011 trivalent influenza vaccine in young children

Christopher C Blyth, Tracy Y Markus, Paul V Effler and Peter C Richmond
Med J Aust 2011; 195 (1): 52.

To the Editor: Young children are at increased risk of severe influenza compared with the general population. Routine vaccination of children using trivalent influenza vaccine (TIV) is recommended in the United States and Canada. The Western Australian government, with support from vaccine manufacturers, has been providing TIV free of charge to all children aged 6–59 months since 2008.1

  • Christopher C Blyth1,2,3
  • Tracy Y Markus3
  • Paul V Effler4
  • Peter C Richmond1,2,3

  • 1 School of Paediatrics and Child Health, University of Western Australia, Perth, WA.
  • 2 Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Perth, WA.
  • 3 Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA.
  • 4 Prevention and Control Program, Communicable Disease Control Directorate, WA Health, Perth, WA.


Acknowledgements: 

We thank Christine Baker, Dale Carcione, Christine Robins, Caroline Wharton, Filomena Mascaro and Nicky Conway for assisting with collation of data.

Competing interests:

Christopher Blyth, Tracy Markus and Peter Richmond are members of the Vaccine Trials Group. The Vaccine Trials Group has received funding for research from vaccine providers including CSL Biotherapies, Sanofi Pasteur and GlaxoSmithKline. Peter Richmond has also previously been a member of a CSL Limited vaccine advisory board.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.